mardi 7 novembre 2017

Onco Actu du 7 novembre 2017

2. Etiologie

Acid reflux drugs linked to increased stomach cancer risk [NHS Choices]

4.10 Dép., diag. & prono. - FDA, EMA, NICE,...

FDA Announces Streamlined Review Pathway for DTC Genetic Tests [RAPS]

FDA clears the way for more consumer genetic health tests to hit the market [STAT]

Statement from FDA Commissioner Scott Gottlieb, M.D., on implementation of agency’s streamlined development and review pathway for consumer tests that evaluate genetic health risks [FDA]

4.11 Dép., diag. & prono. - Ovaire

Levels of Immune Cells within Ovarian Tumors Linked to Survival for Some Patients [NCI]

4.12 Biopsies liquides

Liquid biopsy spots aggressive pediatric brainstem cancer earlier without surgery [Children's National]

New techniques give blood biopsies greater promise [Broad Institute]

4.9 Dép., diag. & prono. - Sein

Hologic and Tromp Medical to provide all mammography systems for the Dutch Breast Cancer Screening Program [HealthCareBusiness]

5. Traitements

Could AstraZeneca’s ovarian cancer drug also treat glioblastoma? [FierceBiotech]

5.12.2 Immunothérapies - CAR-T

FDA Lifts Clinical Hold on Cellectis Phase 1 Clinical Trials with UCART123 in AML and BPDCN [Cellectis]

FDA gives Cellectis a green light to relaunch off-the-shelf CAR-T studies — with several strings attached [EndPoints]

5.12.4 Immunothérapies - Essais

AVEO Oncology and EUSA Pharma Announce Promising Phase 1 Results from the Phase 1/2 TiNivo Study of Tivozanib and Nivolumab in Renal Cell Carcinoma [Aveo]

Opdivo (nivolumab) Demonstrates Superior Three-Year Survival Benefit for Patients with Previously Treated Advanced Renal Cell Carcinoma (RCC) [BMS]

5.12.7 Immunothérapies - vaccins

NousCom bags €42M to trial off-the-shelf cancer vaccine [FierceBiotech]

5.2 Pharma

Merck, Pfizer launch Bavencio for rare skin cancer [PharmaTimes]

Speedy review for Jazz’ high-risk AML chemo [PharmaTimes]

Amgen is shaking up R&D (again), chopping 200 as Genentech targets 130 layoffs [EndPoints]

5.3 Traitements - FDA, EMA, NICE...

Should we accept higher p values than 0.05 for new cancer drugs? [BMJ]

5.3.4 Traitements - AMM (FDA, EMA)

FDA approves Zelboraf (vemurafenib) for Erdheim-Chester disease with BRAF V600 mutation [Roche]

FDA approves Roche’s Alecensa (alectinib) as first-line treatment for people with specific type of lung cancer [Roche]

FDA Approves New BTK-Targeted Therapeutic for Non-Hodgkin Lymphoma [Cancer Research Catalyst]

FDA approves first treatment for certain patients with Erdheim-Chester Disease, a rare blood cancer [FDA]

FDA approves Roche drugs for rare types of blood, lung cancers [Reuters]

6.1 Observation

Fertility preservation with hormone stimulation did not increase risk of breast cancer relapse [Karolinska Institutet]

Eating more fiber tied to lower mortality with colon cancer [Reuters]

6.6 Publications

Court demands that search engines and internet service providers block Sci-Hub [Science]

6.7 DMP, Big Data & applis

Tailored treatment for prostate cancer could save men from devastating side-effects [The Telegraph]

NCRI 2017: Big data analysis predicts risk of radiotherapy effects [Institute of Cancer Research]

NIH awards to test ways to store, access, share, and compute on biomedical data in the cloud [NIH]